SEC Form 4 · accession 0001209191-17-033718
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil F. McFarlane
Officer — Chief Operating Officer
Period of report
May 17, 2017
Accepted (ET)
May 18, 2017 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F1 | $17.44 | May 17, 2017 | A | 90,000 | A | — | May 16, 2027 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable in sixteen equal quarterly installments from the date of grant.